Metronidazole

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer. It is not a veterinary-authorised presentation and this animal use is off-label.

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The whole 500 mg tablet is workable only for a limited range of large dogs at the calculated dose. It cannot accurately serve most dogs without a validated compounded preparation.

The exact human presentation has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer. It is not a veterinary-authorised presentation and this animal use is off-label.

Veterinary labels support susceptible anaerobic infections, while feline Giardia studies and CAPC show variable roughly 50-60% efficacy and safety limitations; this does not support routine use for nonspecific diarrhoea.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

This 500 mg whole-unit human tablet is far above the usual feline dose and metronidazole is intensely bitter. Crushing does not make an unmeasured powder fraction accurate; use a validated lower-strength or compounded veterinary form.

The exact human presentation has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer. It is not a veterinary-authorised presentation and this animal use is off-label.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer. It is not a veterinary-authorised presentation and this animal use is off-label.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human tablet has sourced current registrations in Georgia, EU/EEA and the UK and a transparent strength and form. It is not a veterinary-authorised presentation and this animal use is off-label.

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The whole 500 mg tablet is workable only for a limited range of large dogs at the calculated dose. It cannot accurately serve most dogs without a validated compounded preparation.

The exact human tablet has sourced current registrations in Georgia, EU/EEA and the UK and a transparent strength and form. It is not a veterinary-authorised presentation and this animal use is off-label.

Veterinary labels support susceptible anaerobic infections, while feline Giardia studies and CAPC show variable roughly 50-60% efficacy and safety limitations; this does not support routine use for nonspecific diarrhoea.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

This 500 mg whole-unit human tablet is far above the usual feline dose and metronidazole is intensely bitter. Crushing does not make an unmeasured powder fraction accurate; use a validated lower-strength or compounded veterinary form.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The whole 500 mg tablet is workable only for a limited range of large dogs at the calculated dose. It cannot accurately serve most dogs without a validated compounded preparation.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels support susceptible anaerobic infections, while feline Giardia studies and CAPC show variable roughly 50-60% efficacy and safety limitations; this does not support routine use for nonspecific diarrhoea.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

This 500 mg whole-unit human tablet is far above the usual feline dose and metronidazole is intensely bitter. Crushing does not make an unmeasured powder fraction accurate; use a validated lower-strength or compounded veterinary form.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The whole 250 mg tablet can match a limited medium-to-large-dog weight range, but it cannot accurately deliver many patient-specific doses; use a suitable veterinary strength or validated compound outside that range.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels support susceptible anaerobic infections, while feline Giardia studies and CAPC show variable roughly 50-60% efficacy and safety limitations; this does not support routine use for nonspecific diarrhoea.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

This 250 mg whole-unit human tablet is far above the usual feline dose and metronidazole is intensely bitter. Crushing does not make an unmeasured powder fraction accurate; use a validated lower-strength or compounded veterinary form.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The whole 250 mg tablet can match a limited medium-to-large-dog weight range, but it cannot accurately deliver many patient-specific doses; use a suitable veterinary strength or validated compound outside that range.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels support susceptible anaerobic infections, while feline Giardia studies and CAPC show variable roughly 50-60% efficacy and safety limitations; this does not support routine use for nonspecific diarrhoea.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

This 250 mg whole-unit human tablet is far above the usual feline dose and metronidazole is intensely bitter. Crushing does not make an unmeasured powder fraction accurate; use a validated lower-strength or compounded veterinary form.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The whole 500 mg tablet is workable only for a limited range of large dogs at the calculated dose. It cannot accurately serve most dogs without a validated compounded preparation.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels support susceptible anaerobic infections, while feline Giardia studies and CAPC show variable roughly 50-60% efficacy and safety limitations; this does not support routine use for nonspecific diarrhoea.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

This 500 mg whole-unit human tablet is far above the usual feline dose and metronidazole is intensely bitter. Crushing does not make an unmeasured powder fraction accurate; use a validated lower-strength or compounded veterinary form.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Metronidazole has reliable activity and tissue penetration against susceptible obligate anaerobes, and human IV formulations have an established veterinary role in serious canine anaerobic infection. Outcome evidence for these exact bags is indirect and source control or broader therapy can remain essential.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Activity against susceptible obligate anaerobes and direct feline IV pharmacokinetics support a hospital role, but feline clinical-outcome evidence for human infusion bags is sparse; source control and broader therapy may remain essential.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

The ready-to-use 5 mg/mL infusion permits accurate small-animal dosing in hospital, but the 100 mL single-use bag creates aseptic handling and wastage constraints; infusion compatibility and exact-product instructions must be verified.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.

The whole 500 mg tablet is workable only for a limited range of large dogs at the calculated dose. It cannot accurately serve most dogs without a validated compounded preparation.

The exact human presentation has a sourced current Georgian registration and identifiable strength, route and manufacturer; exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match. It is not veterinary-authorised.

Veterinary labels support susceptible anaerobic infections, while feline Giardia studies and CAPC show variable roughly 50-60% efficacy and safety limitations; this does not support routine use for nonspecific diarrhoea.

Feline PK is documented, but direct safety data are limited; in-vitro genotoxicity and a severe neurotoxicosis case add uncertainty. Avoid unnecessary or prolonged exposure, account for hepatic disease and stop promptly for neurologic signs.

This 500 mg whole-unit human tablet is far above the usual feline dose and metronidazole is intensely bitter. Crushing does not make an unmeasured powder fraction accurate; use a validated lower-strength or compounded veterinary form.

The exact veterinary presentation has a sourced current Georgian registration and independently verified EU/EEA product information defining its strength, species, oral route and regimen. The dossier is transparent, although independent exact-product clinical outcome evidence remains limited.

The authorised spectrum fits mixed susceptible periodontal flora, and a six-dog study found a treatment-time reduction in selected dental-biofilm taxa. It did not test clinical cure, recurrence or superiority, while current dental and stewardship guidance makes source control primary and systemic antibiotics selective rather than routine.

The labelled 5-10-day course has a useful safety margin and gastrointestinal reactions are very rare, but metronidazole adds dose- and duration-related neurologic and genotoxic uncertainty, reproductive safety is not established, and concurrent macrolides are prohibited. Hepatic disease requires particular caution and is contraindicated by the bound Stomorgyl 20 label.

Once-daily dosing for 5-10 days and the 1-tablet/2-kg strength are workable for many cats and small dogs. The tablet must remain whole, so patients whose calculated dose is not a whole 2-kg unit need another authorised strength or presentation.

The exact veterinary presentation has a sourced current Georgian registration and independently verified EU/EEA product information defining its strength, species, oral route and regimen. The dossier is transparent, although independent exact-product clinical outcome evidence remains limited.

The product is authorised for cats and its spectrum plausibly covers susceptible mixed oral flora, but no applicable independent feline clinical outcome trial was found. Dental and stewardship guidance makes source control primary and systemic antibiotics selective, so efficacy confidence is lower than in dogs.

The labelled 5-10-day course has a useful safety margin and gastrointestinal reactions are very rare, but metronidazole adds dose- and duration-related neurologic and genotoxic uncertainty, reproductive safety is not established, and concurrent macrolides are prohibited. Hepatic disease requires particular caution and is contraindicated by the bound Stomorgyl 20 label.

Once-daily dosing for 5-10 days and the 1-tablet/2-kg strength are workable for many cats and small dogs. The tablet must remain whole, so patients whose calculated dose is not a whole 2-kg unit need another authorised strength or presentation.

The exact veterinary presentation has a sourced current Georgian registration and independently verified EU/EEA product information defining its strength, species, oral route and regimen. The dossier is transparent, although independent exact-product clinical outcome evidence remains limited.

The authorised spectrum fits mixed susceptible periodontal flora, and a six-dog study found a treatment-time reduction in selected dental-biofilm taxa. It did not test clinical cure, recurrence or superiority, while current dental and stewardship guidance makes source control primary and systemic antibiotics selective rather than routine.

The labelled 5-10-day course has a useful safety margin and gastrointestinal reactions are very rare, but metronidazole adds dose- and duration-related neurologic and genotoxic uncertainty, reproductive safety is not established, and concurrent macrolides are prohibited. Hepatic disease requires particular caution and is contraindicated by the bound Stomorgyl 20 label.

Once-daily dosing for 5-10 days is simple, but the whole-only 1-tablet/10-kg unit cannot accurately fit many dogs between weight steps. Stomorgyl 2 or 20 should be selected when an authorised whole-unit strength matches better.

The exact veterinary presentation has a sourced current Georgian registration and independently verified EU/EEA product information defining its strength, species, oral route and regimen. The dossier is transparent, although independent exact-product clinical outcome evidence remains limited.

The product is authorised for cats and its spectrum plausibly covers susceptible mixed oral flora, but no applicable independent feline clinical outcome trial was found. Dental and stewardship guidance makes source control primary and systemic antibiotics selective, so efficacy confidence is lower than in dogs.

The labelled 5-10-day course has a useful safety margin and gastrointestinal reactions are very rare, but metronidazole adds dose- and duration-related neurologic and genotoxic uncertainty, reproductive safety is not established, and concurrent macrolides are prohibited. Hepatic disease requires particular caution and is contraindicated by the bound Stomorgyl 20 label.

The tablet must not be divided or crushed and one whole tablet corresponds to 10 kg. That is a poor dose-delivery match for most cats; the exact label itself directs clinicians toward Stomorgyl 2 for feline patients.

The exact veterinary presentation has a sourced current Georgian registration and independently verified EU/EEA product information defining its strength, species, oral route and regimen. The dossier is transparent, although independent exact-product clinical outcome evidence remains limited.

The authorised spectrum fits mixed susceptible periodontal flora, and a six-dog study found a treatment-time reduction in selected dental-biofilm taxa. It did not test clinical cure, recurrence or superiority, while current dental and stewardship guidance makes source control primary and systemic antibiotics selective rather than routine.

The labelled 5-10-day course has a useful safety margin and gastrointestinal reactions are very rare, but metronidazole adds dose- and duration-related neurologic and genotoxic uncertainty, reproductive safety is not established, and concurrent macrolides are prohibited. Hepatic disease requires particular caution and is contraindicated by the bound Stomorgyl 20 label.

Once-daily dosing for 5-10 days is simple for an appropriately sized dog, but this dog-only whole tablet corresponds to 20 kg and cannot accurately fit many patients. The bound label also excludes dogs below 5 kg.

The exact human presentation has sourced current registrations in Georgia and EU/EEA with identifiable strength, route and manufacturer. It is not a veterinary-authorised presentation and this animal use is off-label.

Veterinary labels and EMA review support susceptible anaerobic infections and selected giardiasis, but controlled studies do not support routine metronidazole for uncomplicated acute diarrhoea and Giardia cure depends on reinfection control.

Gastrointestinal adverse effects and marked microbiome disruption are relevant, and cumulative exposure can cause vestibulocerebellar neurotoxicity at lower doses than historically assumed. Reduce exposure in hepatic dysfunction and stop promptly for neurologic signs.